J. Griffin

发表

STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications

T. Jacks, D. Tuveson, J. Fletcher, 2001, Oncogene.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Donna Neuberg, Steven M Kornblau, Johannes Köster, 2016, Cancer cell.

FOXO3a Regulates Survival and Proliferative Signaling Through Modulation of The NPM-ALK Fusion Kinase of Anaplastic Large Cell Lymphoma

J. Griffin, D. Gilliland, Z. Tothova, 2013 .

FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins

J. Griffin, B. Scheijen, H. Ngo, 2004, Oncogene.

NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a.

J. Griffin, D. Gilliland, Z. Tothova, 2004, Blood.

Mechanisms of Transformation by the BCR/ABL Oncogene

James D. Griffin, J. Griffin, M. Sattler, 2001, International journal of hematology.

rel Is rapidly tyrosine-phosphorylated following granulocyte-colony stimulating factor treatment of human neutrophils.

B. Franza, B. Druker, J. Griffin, 1994, The Journal of biological chemistry.

The cytokine-activated tyrosine kinase JAK2 activates Raf-1 in a p21ras-dependent manner.

K. Xia, T. Roberts, A. D’Andrea, 1996, Proceedings of the National Academy of Sciences of the United States of America.

Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anti-cancer drug activity

K. Anderson, N. Munshi, D. McMillin, 2010, Nature Medicine.

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.

K. Bhalla, H. Kantarjian, J. Cortes, 2006, The New England journal of medicine.

The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors.

B. Ebert, J. Griffin, D. Frank, 2011, Blood.

Expression of the M-CSF (CSF-1) gene by human monocytes.

J. Griffin, A. Rambaldi, D. Young, 1987 .

Independent regulation of M-CSF and G-CSF gene expression in human monocytes.

E. Vellenga, J. Griffin, T. Ernst, 1988, Blood.

Regulation of granulocyte- and monocyte-colony stimulating factor mRNA levels in human blood monocytes is mediated primarily at a post-transcriptional level.

G. Demetri, J. Griffin, T. Ernst, 1989, The Journal of biological chemistry.

The roles of FLT3 in hematopoiesis and leukemia.

J. Griffin, D. Gilliland, James D Griffin, 2002, Blood.

Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles.

Stefan Fröhling, Benjamin L Ebert, Todd R Golub, 2007, Cancer cell.

Growth Suppression of Pre-T Acute Lymphoblastic Leukemia Cells by Inhibition of Notch Signaling

James D. Griffin, Andrew P. Weng, Jon C. Aster, 2003, Molecular and Cellular Biology.

The Adapter Protein Crkl Links Cbl to C3G after Integrin Ligation and Enhances Cell Migration*

J. Griffin, N. Uemura, 1999, The Journal of Biological Chemistry.

Mechanisms of resistance imatinib (STI571) in preclinical models and in leukemia patients.

J. Griffin, E. Weisberg, James D. Griffin, 2001, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

Aminopeptidase Inhibitors Inhibit Proliferation and Induce Apoptosis of K562 and STI571-resistant K562 Cell Lines Through the MAPK and GSK-3ß Pathways

J. Griffin, M. Kizaki, Y. Miyakawa, 2003, Leukemia & lymphoma.

Clonogenic cells in acute myeloblastic leukaemia.

J. Griffin, K. Sabbath, J D Griffin, 2009, Scandinavian journal of haematology.

PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder.

D. Fabbro, J. Kutok, J. Fletcher, 2004, Proceedings of the National Academy of Sciences of the United States of America.

The TEL/ARG leukemia oncogene promotes viability and hyperresponsiveness to hematopoietic growth factors

J. Griffin, K. Okuda, Y. Sonoda, 2004, International journal of hematology.

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

Peter Marynen, Rafeul Alam, Jan Cools, 2003, The New England journal of medicine.

The biology of signal transduction inhibition: basic science to novel therapies.

J. Griffin, James D. Griffin, 2001, Seminars in oncology.

The ABL kinase inhibitor STI571 does not affect survival of hematopoietic cells after ionizing radiation.

J. Griffin, N. Uemura, 2000, Blood.

Signal transduction of the human granulocyte-macrophage colony-stimulating factor and interleukin-3 receptors involves tyrosine phosphorylation of a common set of cytoplasmic proteins.

S. Cannistra, B. Druker, J. Griffin, 1990, Blood.

Tyrosine phosphorylation of rasGAP and associated proteins in chronic myelogenous leukemia cell lines.

R. Salgia, T. Roberts, B. Druker, 1992, Blood.

Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line.

R. Salgia, B. Druker, J. Griffin, 1993, Experimental hematology.

Shc phosphorylation in myeloid cells is regulated by granulocyte macrophage colony-stimulating factor, interleukin-3, and steel factor and is constitutively increased by p210BCR/ABL.

R. Salgia, M. Hallek, B. Druker, 1994, The Journal of biological chemistry.

The SH2 domain of ABL is not required for factor-independent growth induced by BCR-ABL in a murine myeloid cell line.

B. Druker, J. Griffin, T. Matsuguchi, 1995, Leukemia.

p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines.

T. Golub, J. Griffin, K. Okuda, 1996, Oncogene.

Formation of methotrexate polyglutamates in purified myeloid precursor cells from normal human bone marrow.

G. Curt, J. Griffin, R. Fine, 1985, The Journal of clinical investigation.

cdc2 gene expression at the G1 to S transition in human T lymphocytes.

H. Piwnica-Worms, J. Griffin, Y. Furukawa, 1990, Science.

The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.

M. Loh, S. Armstrong, E. Estey, 2005, Blood.

Surface immunoglobulin-mediated signal transduction involves rapid phosphorylation and activation of the protooncogene product Raf-1 in human B-cells.

B. Druker, J. Griffin, I. Matsumura, 1992, Cancer research.

Treatment patterns and healthcare resource utilization in patients with FLT3‐mutated and wild‐type acute myeloid leukemia: A medical chart study

J. Griffin, M. Shah, Yan Song, 2019, European journal of haematology.

Transformation of Myeloid Cells by the BCR/ABL Oncogene

R. Salgia, J. Griffin, M. Sattler, 1998 .

BCR/ABL and Signal Transduction Pathways

R. Salgia, J. Griffin, K. Okuda, 1997 .

Management of chronic myelogenous leukemia.

J. Griffin, 1986, Seminars in hematology.

Effects of recombinant human granulocyte and macrophage colony-stimulating factors on signal transduction pathways in human granulocytes.

J. Griffin, T. Meshulam, A. Schafer, 1987, Journal of immunology.

Effects of recombinant human granulocyte-macrophage colony-stimulating factor on intracellular pH in mature granulocytes.

J. Griffin, Richard, J. Wright, 1988, Blood.

Granulocyte-macrophage colony-stimulating factor and other cytokines regulate surface expression of the leukocyte adhesion molecule-1 on human neutrophils, monocytes, and their precursors.

M. Belvin, J. Griffin, Y. Kanakura, 1990, Journal of immunology.

Differentiation-associated expression of two functionally distinct classes of granulocyte-macrophage colony-stimulating factor receptors by human myeloid cells.

S. Cannistra, J. Griffin, M. Koenigsmann, 1990, The Journal of biological chemistry.

Granulocyte-macrophage colony-stimulating factor and interleukin-3 induce rapid phosphorylation and activation of the proto-oncogene Raf-1 in a human factor-dependent myeloid cell line.

T. Roberts, B. Druker, J. Griffin, 1991, Blood.

BCR/ABL Directly Inhibits Expression of SHIP, an SH2-Containing Polyinositol-5-Phosphatase Involved in the Regulation of Hematopoiesis

J. Griffin, S. Verma, M. Sattler, 1999, Molecular and Cellular Biology.

Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motility

B. Rollins, W. Richards, D. Sugarbaker, 1999, Oncogene.

Leukocyte adhesion molecule-1 (LAM-1, L-selectin) interacts with an inducible endothelial cell ligand to support leukocyte adhesion.

F. Luscinskas, J. Griffin, M. Gimbrone, 1991, Journal of immunology.

JAK2 associates with the beta c chain of the receptor for granulocyte-macrophage colony-stimulating factor, and its activation requires the membrane-proximal region

N. Sato, J. Ihle, J. Griffin, 1994, Molecular and cellular biology.

t(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway

G. Tonon, F. Kaye, A. El‐Naggar, 2003, Nature Genetics.

Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia.

K. Anderson, A. Freedman, J. Griffin, 1992, Blood.

CD10 (CALLA)/neutral endopeptidase 24.11 modulates inflammatory peptide-induced changes in neutrophil morphology, migration, and adhesion proteins and is itself regulated by neutrophil activation.

M. Shipp, E. Reinherz, J. Griffin, 1991, Blood.

NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma.

K. Anderson, N. Munshi, P. Atadja, 2003, Blood.

The c-Mpl Ligand (Thrombopoietin) Stimulates Tyrosine Phosphorylation of Jak2, Shc, and c-Mpl (*)

J. Griffin, K. Kaushansky, J. Drachman, 1995, The Journal of Biological Chemistry.

The thrombopoietin receptor c-MPL activates JAK2 and TYK2 tyrosine kinases.

R. Salgia, J. Griffin, K. Kaushansky, 1995, Experimental hematology.

Purification of common acute lymphoblastic leukemia antigen positive cells from normal human bone marrow.

J. Ritz, J. Griffin, L. Nadler, 1984, Blood.

The retinoblastoma-susceptibility gene product becomes phosphorylated in multiple stages during cell cycle entry and progression.

D. Livingston, J. Decaprio, J. Griffin, 1992, Proceedings of the National Academy of Sciences of the United States of America.

Acute Myeloblastic Leukemia

E. Vellenga, J. Griffin, D. Young, 1996 .

Inhibition of the deubiquitinase USP10 induces degradation of SYK

N. Gray, Jinhua Wang, J. Griffin, 2020, British Journal of Cancer.

The biology of GM-CSF: regulation of production and interaction with its receptor.

G. Demetri, S. Cannistra, J. Griffin, 1990, International journal of cell cloning.

Tissue factor gene expression in acute myeloblastic leukemia.

G. Demetri, J. Griffin, W. Konigsberg, 1989, Thrombosis research.

Reduction of experimental canine myocardial reperfusion injury by a monoclonal antibody (anti-Mo1, anti-CD11b) that inhibits leukocyte adhesion.

P. J. Simpson, J. Griffin, B. Lucchesi, 1988, The Journal of clinical investigation.

RANK‐Fc in myeloma

K. Anderson, N. Munshi, P. Richardson, 2002, Cancer research.

Point mutations in the FLT3 gene in AML.

J. Griffin, 2001, Blood.

Regulation of G1/S transition by cyclins D2 and D3 in hematopoietic cells.

F. Ajchenbaum‐Cymbalista, J. Griffin, K. Ando, 1993, Proceedings of the National Academy of Sciences of the United States of America.

Differential expression and signaling of CBL and CBL-B in BCR/ABL transformed cells

R. Salgia, H. Husson, J. Griffin, 2002, Oncogene.

Inhibition of USP10 induces degradation of oncogenic FLT3.

A. Letai, K. Anderson, N. Gray, 2017, Nature chemical biology.

Modulation of Notch signaling by mastermind-like (MAML) transcriptional co-activators and their involvement in tumorigenesis.

J. Griffin, Lizi Wu, 2004, Seminars in cancer biology.

Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2

J. Marto, J. Griffin, R. Stone, 2021, Leukemia.

of the Myc and Pim proto-oncogenes requires a functional FERM domain for transformation and for expression The Jak2V617F oncogene associated with myeloproliferative diseases

S. Constantinescu, J. Griffin, D. Gilliland, 2013 .

leukemia or chronic lymphocytic leukemia leukemia and acute myeloid leukemia, but not in acute lymphoblastic The JAK2V617F activating mutation occurs in chronic myelomonocytic

Avis J. Thomas, M. Loh, S. Armstrong, 2013 .

Jak2 in peripheral-blood samples A sensitive high-throughput method to detect activating mutations of

P. Jänne, J. Griffin, A. Reiter, 2011 .

The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes.

M. Tomasson, S. Constantinescu, J. Griffin, 2008, Blood.

A sensitive high-throughput method to detect activating mutations of Jak2 in peripheral-blood samples.

P. Jänne, J. Griffin, A. Reiter, 2006, Blood.

Activated Jak2 with the V617F Point Mutation Promotes G1/S Phase Transition*

D. Neuberg, J. Griffin, Jessica L. Gramlich, 2006, Journal of Biological Chemistry.

The JAK 2 V 617 F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia , but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia

M. Loh, S. Armstrong, E. Estey, 2005 .

acute lymphoblastic The JAK 2 V 617 F activating mutation occurs in chronic myelomonocytic

M. Loh, S. Armstrong, E. Estey, 2005 .

Comparing nilotinib with dasatinib as second-line therapies in patients with chronic myelogenous leukemia resistant or intolerant to imatinib – a retrospective chart review analysis

J. Griffin, R. Ionescu-Ittu, E. Wu, 2013, Current medical research and opinion.

Midostaurin, a Natural Product-Derived Kinase Inhibitor Recently Approved for the Treatment of Hematological MalignanciesPublished as part of the Biochemistry series "Biochemistry to Bedside".

J. Griffin, P. Manley, M. Sattler, 2017, Biochemistry.

Inhibition of mutant FLT 3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC 412

D. Fabbro, T. Meyer, J. Griffin, 2002 .

Effects of the multi‐kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia

N. Gray, Jinhua Wang, J. Griffin, 2020, Journal of cellular and molecular medicine.

Identification of a Family of Mastermind-Like Transcriptional Coactivators for Mammalian Notch Receptors

T. Sun, J. Griffin, P. Gao, 2002, Molecular and Cellular Biology.

Advances in Brief Prediction of Resistance to Small Molecule FLT 3 Inhibitors : Implications for Molecularly Targeted Therapy of Acute Leukemia

D. Fabbro, P. Marynen, P. Furet, 2004 .

Resistance to targeted therapy in leukaemia

J. Griffin, 2002, The Lancet.

Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia.

B. Druker, J. Griffin, K. Okuda, 1994, The Journal of biological chemistry.

Expression and state of phosphorylation of the retinoblastoma susceptibility gene product in cycling and noncycling human hematopoietic cells.

D. Livingston, J. Decaprio, A. Freedman, 1990, Proceedings of the National Academy of Sciences of the United States of America.

AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has In vitro Activity against Imatinib-Resistant Chronic Myeloid Leukemia

J. Mestan, H. Kantarjian, J. Cortes, 2005, Clinical Cancer Research.

acute myeloid leukemia cells Anti-MY9-blocked-ricin: an immunotoxin for selective targeting of

M. Belvin, J. Ritz, J. Griffin, 2011 .

Anti-MY9-blocked-ricin: an immunotoxin for selective targeting of acute myeloid leukemia cells.

M. Belvin, J. Ritz, J. Griffin, 1991, Blood.

Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity Comparison.

P. Furet, P. Imbach, G. Bold, 2010, Genes & cancer.

Prognostic value of lymphocyte surface markers in acute myeloid leukemia.

J. Griffin, R. Mayer, D. Arthur, 1991, Blood.

Lymphocytic thymoma associated with T-cell lymphocytosis.

J. Griffin, A. Aisenberg, J. Long, 1978, The American journal of medicine.

NADPH oxidases regulate cell growth and migration in myeloid cells transformed by oncogenic tyrosine kinases

R. Salgia, R. Levine, J. Griffin, 2010, Leukemia.

Structure of the gene encoding the human leukocyte adhesion molecule-1 (TQ1, Leu-8) of lymphocytes and neutrophils.

J. Griffin, Liangji Zhou, T. Ernst, 1990, The Journal of biological chemistry.

dependent mechanism stimulate monocyte cytotoxicity through a tumor necrosis factor- Human granulocyte-monocyte colony-stimulating factor and interleukin 3

E. Vellenga, S. Cannistra, J. Griffin, 2011 .

Human granulocyte-monocyte colony-stimulating factor and interleukin 3 stimulate monocyte cytotoxicity through a tumor necrosis factor-dependent mechanism.

E. Vellenga, S. Cannistra, J. Griffin, 1988, Blood.

mesothelial cells and human malignant mesothelioma cells lines in vitro Expression of colony-stimulating factor genes by normal human

G. Demetri, J. Griffin, J. Rheinwald, 2011 .

Treatment of myeloid leukemic cells with the phosphatase inhibitor okadaic acid induces cell cycle arrest at either G1/S or G2/M depending on dose

J. Decaprio, J. Griffin, Y. Furukawa, 1992, Journal of cellular physiology.

Expression of a novel 3.5-kb macrophage colony-stimulating factor transcript in human myeloma cells.

K. Anderson, G. Demetri, A. Freedman, 1989, Journal of Immunology.

Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU‐285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies

N. Gray, Jinhua Wang, J. Griffin, 2019, British journal of haematology.

Stromal-Derived Factor-1? The BCR/ABL Oncogene Alters the Chemotactic Response to

G. Daley, J. Griffin, M. Sattler, 2012 .

Abnormal response to granulocyte colony-stimulating factor (G-CSF) in canine cyclic hematopoiesis is not caused by altered G-CSF receptor expression.

B. Druker, J. Griffin, V. Broudy, 1994, Blood.

Phorbol 12-myristate 13-acetate inhibits granulocyte-macrophage colony stimulating factor-induced protein tyrosine phosphorylation in a human factor-dependent hematopoietic cell line.

S. Cannistra, B. Druker, J. Griffin, 1991, The Journal of biological chemistry.

Signal transduction of interleukin-6 involves tyrosine phosphorylation of multiple cytosolic proteins and activation of Src-family kinases Fyn, Hck, and Lyn in multiple myeloma cell lines.

M. Hallek, B. Druker, J. Griffin, 1997, Experimental hematology.

Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment.

J. Mestan, D. Fabbro, P. Furet, 2004, Mini reviews in medicinal chemistry.

Internalization of the granulocyte-macrophage colony-stimulating factor receptor is not required for induction of protein tyrosine phosphorylation in human myeloid cells.

B. Druker, J. Griffin, K. Okuda, 1991, Blood.

Signal transduction and cellular functions of the TEL/ARG oncoprotein

J. Griffin, K. Okuda, A. Oda, 2005, Leukemia.

The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.

P. Marynen, H. Drexler, J. Griffin, 2004, Blood.

The Mastermind-like 1 (MAML1) Co-activator Regulates Constitutive NF-κB Signaling and Cell Survival*

J. Griffin, Shuibin Lin, Lizi Wu, 2010, The Journal of Biological Chemistry.

Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles.

T. Golub, S. Fröhling, B. Ebert, 2007, Cancer cell.

A low affinity chimeric human alpha/beta-granulocyte-macrophage colony-stimulating factor receptor induces ligand-dependent proliferation in a murine cell line.

A. Ganser, J. Griffin, R. Inhorn, 1994, The Journal of biological chemistry.

SHIP1, an SH2 Domain Containing Polyinositol-5-phosphatase, Regulates Migration through Two Critical Tyrosine Residues and Forms a Novel Signaling Complex with DOK1 and CRKL*

R. Salgia, J. Griffin, S. Verma, 2001, The Journal of Biological Chemistry.

Preexposure of resting B cells to interferon-gamma enhances their proliferative response to subsequent activation signals.

A. Freedman, J. Griffin, D. Fisher, 1987, Cellular immunology.

The C-terminus of c-ABL is required for proliferation and viability signaling in a c-ABL/erythropoietin receptor fusion protein.

A. D’Andrea, J. Griffin, R. V. van Etten, 1998, Blood.

The C-Terminus of c-Abl Is Required for Proliferation and Viability Signaling in a c-Abl/Erythropoietin Receptor Fusion Protein

A. D’Andrea, J. Griffin, R. A. Etten, 1998 .

Identification of a viability domain in the granulocyte/macrophage colony-stimulating factor receptor beta-chain involving tyrosine-750.

J. Griffin, D. Frank, R. Inhorn, 1995, Proceedings of the National Academy of Sciences of the United States of America.

CML cell trafficking: Influence of the stromal microenvironment

J. Griffin, E. Weisberg, 2012 .

Role of B 7-1 in Mediating an Immune Response to Myeloid Leukemia Cells

G. Freeman, J. Griffin, L. Nadler, 2002 .

Role of B7-1 in mediating an immune response to myeloid leukemia cells.

G. Freeman, J. Griffin, U. Matulonis, 1995, Blood.

Two functional domains in the phagocyte membrane glycoprotein Mo1 identified with monoclonal antibodies.

M. Klempner, M. Arnaout, J. Griffin, 1986, Journal of immunology.

Bcr/Abl expression stimulates integrin function in hematopoietic cell lines.

J. Griffin, G. Bazzoni, N. Carlesso, 1996, The Journal of clinical investigation.

leukemia: direct analysis using partially purified colony- forming cells Expression of Ia antigens on myeloid progenitor cells in chronic myeloid

S. Cannistra, J. Griffin, J. Daley, 2011 .

Differential expression of HLA-DR antigens in subsets of human CFU-GM.

S. Cannistra, F. Herrmann, J. Griffin, 1985, Blood.

Expression of Ia antigens on myeloid progenitor cells in chronic myeloid leukemia: direct analysis using partially purified colony- forming cells

S. Cannistra, J. Griffin, J. Daley, 1985 .

Expression of Ia antigens on myeloid progenitor cells in chronic myeloid leukemia: direct analysis using partially purified colony-forming cells.

S. Cannistra, J. Griffin, J. Daley, 1985, Blood.

Factor independence of human myeloid leukemia cell lines is associated with increased phosphorylation of the proto-oncogene Raf-1.

R. Salgia, B. Druker, J. Griffin, 1994, Experimental hematology.

Constitutive expression of the granulocyte-macrophage colony-stimulating factor gene in acute myeloblastic leukemia.

J. Griffin, D. Young, K. Wagner, 1987, The Journal of clinical investigation.

phosphorylation in human myeloid cells factor receptor is not required for induction of protein tyrosine Internalization of the granulocyte-macrophage colony-stimulating

B. Druker, J. Griffin, K. Okuda, 2011 .

Reversible Resistance Induced by FLT3 Inhibition: A Novel Resistance Mechanism in Mutant FLT3-Expressing Cells

Chengsheng Zhang, J. Griffin, E. Fox, 2011, PloS one.

Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors.

D. Lauffenburger, P. Sorger, N. Gray, 2017, Bioorganic & medicinal chemistry.

Causative Factors Involved in Development of Resistance to Tyrosine Kinase Inhibition and Novel Strategies Designed to Override This Resistance

J. Griffin, E. Weisberg, 2011 .

Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia.

S. Cannistra, J. Griffin, P. Groshek, 1989, Leukemia.

Involvement of spermidine in proliferation and differentiation of human promyelocytic leukemia cells.

J. Griffin, D. Kufe, T. Shafman, 1984, Blood.

Secretion of interleukin-1 by acute myeloblastic leukemia cells in vitro induces endothelial cells to secrete colony stimulating factors.

E. Vellenga, S. Cannistra, J. Griffin, 1987, Blood.

BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma

Edmund M. Harrington, W. Ni, W. Forrester, 2022, Blood Cancer Journal.

Phenotypic complementation of the SV40 tsA mutant defect in viral DNA synthesis following microinjection of SV40 T antigen

D. Livingston, J. Griffin, M. Kriegler, 1978, Cell.

Cloning and expression of a gamma-interferon-inducible gene in monocytes: a new member of a cytokine gene family.

G. Freeman, E. Reinherz, J. Griffin, 1989, International immunology.

Generation of monoclonal antibodies to a human natural killer clone. Characterization of two natural killer-associated antigens, NKH1A and NKH2, expressed on subsets of large granular lymphocytes.

J. Ritz, J. Griffin, J. Daley, 1985, The Journal of clinical investigation.

Human granulocyte-macrophage colony-stimulating factor induces expression of the tumor necrosis factor gene by the U937 cell line and by normal human monocytes.

S. Cannistra, F. Herrmann, J. Griffin, 1987, The Journal of clinical investigation.

Regulation of leukocyte adhesion molecule-1 (TQ1, Leu-8) expression and shedding by normal and malignant cells.

M. Belvin, A. Freedman, J. Griffin, 1991, Leukemia.

Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

M. Dimopoulos, K. Konstantopoulos, M. Mohty, 2021, The Lancet.

Expression of interleukin 2 receptors and binding of interleukin 2 by gamma interferon-induced human leukemic and normal monocytic cells

S. Cannistra, F. Herrmann, J. Griffin, 1985, The Journal of experimental medicine.

A Fragment of Paxillin Binds the α4Integrin Cytoplasmic Domain (Tail) and Selectively Inhibits α4-Mediated Cell Migration*

R. Salgia, C. Turner, J. Griffin, 2002, The Journal of Biological Chemistry.

A fragment of paxillin binds the alpha 4 integrin cytoplasmic domain (tail) and selectively inhibits alpha 4-mediated cell migration.

R. Salgia, C. Turner, J. Griffin, 2002, The Journal of biological chemistry.

The human granulocyte‐macrophage colony‐stimulating factor receptor is capable of initiating signal transduction in NIH3T3 cells.

J. Griffin, T. Ernst, M. Eder, 1993, The EMBO journal.

The BCR/ABL Tyrosine Kinase Induces Production of Reactive Oxygen Species in Hematopoietic Cells*

R. Salgia, J. Griffin, S. Verma, 2000, The Journal of Biological Chemistry.

Enhancement of superoxide anion release by granulocytes harvested from patients receiving granulocyte‐macrophage colony‐stimulating factor

M. Socinski, J. Griffin, A. Elias, 1989, British journal of haematology.

Expression of the M-CSF (CSF-1) gene by human monocytes.

J. Griffin, A. Rambaldi, D. Young, 1987, Blood.

Measurements of the molecular size of the simian virus 40 large T antigen

D. Livingston, J. Griffin, S. Light, 1978, Journal of virology.

Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma

N. Gray, Qingsong Liu, D. McMillin, 2014, ACS chemical biology.

Diagnosis and treatment of human leukemias and lymphomas utilizing monoclonal antibodies.

E. Reinherz, J. Ritz, J. Griffin, 1981, Progress in hematology.

Hematopoietic growth factors and high-dose chemotherapy: will grams succeed where milligrams fail?

G. Demetri, J. Griffin, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

p210Bcr/Abl and p160v-Abl induce an increase in the tyrosine phosphorylation of p93c-Fes.

J. Griffin, T. Ernst, K. Slattery, 1994, The Journal of biological chemistry.

Independent regulation of human D-type cyclin gene expression during G1 phase in primary human T lymphocytes.

J. Decaprio, J. Griffin, K. Ando, 1993, The Journal of biological chemistry.

Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia

James D. Griffin, Andreas Hochhaus, J. Griffin, 2007, Nature Reviews Cancer.

Expression of MY7 antigen on myeloid precursor cells.

J. Ritz, J. Griffin, J. Daley, 1983, International journal of cell cloning.

Use of SM-1 monoclonal antibody and human complement in selective killing of small cell carcinoma of the lung.

R. Stahel, J. Griffin, M. Mabry, 1985, The Journal of clinical investigation.

Characterization of an antigen expressed by human natural killer cells.

J. Griffin, S. Schlossman, T. Hercend, 1983, Journal of immunology.

Relationship between HLA-DR expression by normal myeloid progenitor cells and inhibition of colony growth by prostaglandin E. Implications for prostaglandin E resistance in chronic myeloid leukemia.

S. Cannistra, F. Herrmann, J. Griffin, 1986, The Journal of clinical investigation.

Isolation of myeloid progenitor cells from peripheral blood of chronic

J. Griffin, S. Schlossman, R. Beveridge, 1982 .

Isolation of myeloid progenitor cells from peripheral blood of chronic myelogenous leukemia patients.

J. Griffin, S. Schlossman, R. Beveridge, 1982, Blood.

Corrigendum: Tyrosine phosphorylation of p95(Vav) in myeloid cells is regulated by GM-CSF, IL-3 and Steel factor and is constitutively increased by p210(BCR/ABL) (The EMBO Journal (1995) 14 (257-265))

B. Druker, J. Griffin, T. Matsuguchi, 1996 .

Polyamine requirements for induction of HL-60 promyelocyte differentiation by leukocyte-conditioned medium and phorbol ester.

J. Griffin, D. Kufe, T. Shafman, 1984, Cancer research.

Effect of ara-A on differentiation and proliferation of HL-60 cells.

J. Griffin, D. Kufe, D. Munroe, 1984, Leukemia research.

Expression of normal monocyte-macrophage differentiation antigens on HL60 promyelocytes undergoing differentiation induced by leukocyte-conditioned medium or phorbol diester.

J. Ritz, J. Griffin, L. Nadler, 1981, Leukemia research.

Development of a histiocytic medullary reticulosis-like syndrome during the course of acute lymphocytic leukemia.

J. Griffin, A. Dvorak, J. Long, 1978, The American journal of medicine.

In vitro regulation of human hematopoiesis by natural killer cells: analysis at a clonal level.

J. Ritz, F. Herrmann, J. Griffin, 1987, Blood.

The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations.

J. Griffin, A. Christie, A. Kung, 2012, Genes & cancer.

Monocyte interleukin-1 secretion is regulated by the sequential action of gamma-interferon and interleukin-2 involving monocyte surface expression of interleukin-2 receptors.

S. Cannistra, F. Herrmann, M. Brach, 1989, Haematology and blood transfusion.

Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia.

S. Cannistra, J. Griffin, R. Mayer, 1991, Leukemia.

Effects of recombinant IL-3, GM-CSF, and G-CSF on proliferation of leukemic clonogenic cells in short-term and long-term cultures.

E. Vellenga, J. Griffin, D. Ostapovicz, 1987, Leukemia.

Effects of recombinant human GM-CSF on proliferation of clonogenic cells in acute myeloblastic leukemia.

F. Herrmann, J. Griffin, K. Sabbath, 1986, Blood.

Leukemic colony-forming cells in acute myeloblastic leukemia: maturation hierarchy and growth conditions.

B. Dörken, A. Ganser, F. Herrmann, 1987, Haematology and blood transfusion.

T cell-monocyte interactions in the production of humoral factors regulating human granulopoiesis in vitro.

S. Cannistra, F. Herrmann, J. Griffin, 1986, Journal of immunology.

Clinical pharmacology of low-dose cytosine arabinoside.

J. Griffin, D. Kufe, D. Spriggs, 1985, Blood.

Response of preleukemic syndromes to continuous infusion of low-dose cytarabine.

J. Griffin, D. Kufe, J. Wisch, 1983, The New England journal of medicine.

Cellular and clinical pharmacology of low-dose ara-C.

J. Griffin, D. Kufe, D. Spriggs, 1985, Seminars in oncology.

Identification and purification of human erythroid progenitor cells by monoclonal antibody to the transferrin receptor (TÜ 67)

P. Wernet, F. Herrmann, J. Griffin, 1988, Blut.

A blast subclone of the HL-60 human promyelocytic cell line.

M. Minden, J. Griffin, D. Kufe, 1981, Leukemia research.

Pharmacologic studies of low-dose and high-dose continuous infusion cytosine arabinoside.

J. Griffin, D. Kufe, D. Spriggs, 1987, Seminars in oncology.

Generation of Monoclonal Antibodies to a Human Natural Killer Clone

J. Ritz, J. Griffin, J. Daley, 2022 .

Effect of phorbol ester on differentiation of human myeloid colony forming cells (CFU-C).

J. Griffin, S. Schlossman, R. Beveridge, 1983, Leukemia research.

The transcriptional coactivator Maml1 is required for Notch2-mediated marginal zone B-cell development.

W. Pear, J. Griffin, I. Maillard, 2007, Blood.

Clonal chromosomal abnormalities showing multiple-cell-lineage involvement in acute myeloid leukemia.

A. de la Chapelle, J. Griffin, C. Bloomfield, 1988, The New England journal of medicine.

Recombinant Human Gamma Interferon Administered by Continuous Intravenous Infusion in Acute Myelogenous Leukemia and Myelodysplastic Syndromes

J. Griffin, D. Kufe, R. Mayer, 1993, American journal of clinical oncology.

Treatment of preleukemic syndromes with continuous intravenous infusion of low-dose cytosine arabinoside.

J. Griffin, D. Kufe, D. Spriggs, 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias.

D. Fabbro, J. Griffin, A. Kung, 2007, Blood.

myelogenous leukemia cells resistant to kinase inhibitors The STAT5 inhibitor pimozide decreases survival of chronic

J. Griffin, S. R. Walker, E. Weisberg, 2011 .

The biology of acute myeloblastic leukemia.

E. Vellenga, J. Griffin, 1987, Seminars in oncology.

BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin.

Christian Sillaber, Peter Valent, J. Griffin, 2002, Blood.

Identification of Novel Splice Variants of Multiple Genes Using Genome-Wide Analysis of Alternative Splicing in Patients with Acute Myeloid Leukemia.

J. Griffin, R. Stone, M. Bar‐Natan, 2009 .

The effects of GM-CSF and G-CSF in promoting growth of clonogenic cells in acute myeloblastic leukemia.

E. Vellenga, J. Griffin, D. Young, 1987, Blood.

A Two-Color Flow Cytometry Assay for Detection of Hairy Cells Using Monoclonal Antibodies

Griffin, Nadler, R., 2005 .

Use of surface markers to identify a subset of acute myelomonocytic leukemia cells with progenitor cell properties.

J. Griffin, S. Schlossman, P. Larcom, 1983, Blood.

Differential Signaling after β1 Integrin Ligation Is Mediated Through Binding of CRKL to p120 CBL and p110 HEF1 *

R. Salgia, E. Golemis, J. Griffin, 1997, The Journal of Biological Chemistry.

B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct.

G. Freeman, J. Griffin, U. Matulonis, 1996, Journal of immunology.

Cdk4 integrates growth stimulatory and inhibitory signals during G1 phase of hematopoietic cells.

J. Griffin, K. Ando, K. Ando, 1995, Oncogene.

Patupilone (epothilone B) inhibits growth and survival of multiple myeloma cells in vitro and in vivo.

C. Mitsiades, J. Griffin, D. Chauhan, 2005, Blood.

Differential expression of CD11b/CD18 (Mo1) and myeloperoxidase genes during myeloid differentiation.

D. Tenen, M. Arnaout, J. Griffin, 1989, Blood.

Amsacrine in refractory acute leukemia.

J. Griffin, R. Mayer, M. Maguire, 1985, Cancer treatment reports.

Relationship of oligomerization to enzymatic and DNA-binding properties of the SV40 large T antigen

D. Livingston, J. Griffin, M. Bradley, 1982, Cell.

Identification and initial characterization of a new low-molecular-weight virus-encoded T antigen in a line of simian virus 40-transformed cells

D. Livingston, J. Griffin, H. Rubin, 1980, Journal of virology.

The effects of phorbol myristate acetate and chemotactic peptide on transmembrane potentials and cytosolic free calcium in mature granulocytes evolve sequentially as the cells differentiate.

J. Griffin, T. Meshulam, H. Malech, 1987, The Journal of biological chemistry.

MAML1, a human homologue of Drosophila Mastermind, is a transcriptional co-activator for NOTCH receptors

James D. Griffin, Jon C. Aster, Stephen C. Blacklow, 2000, Nature Genetics.

The Transcriptional Coactivator Maml 1 is Required for Notch 2-mediated Marginal Zone B cell Development

W. Pear, J. Griffin, I. Maillard, 2007 .

Cloning and functional characterization of the murine mastermind-like 1 (Maml1) gene.

T. Sun, J. Griffin, N. Mukhopadhyay, 2004, Gene.

positive chronic eosinophilic leukemia - The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA

P. Marynen, H. Drexler, J. Griffin, 2013 .

Mb1, a plasma membrane antigen selectively expressed by U-937 cells.

J. Griffin, A. Biondi, R. Todd, 1985, Blood.

An enzyme-linked immunosorbent assay (ELISA) for the detection of monoclonal antibodies to cell surface antigens on viable cells.

H. Lazarus, J. Griffin, M. Posner, 1982, Journal of immunological methods.

Cell-Surface Antigens in Acute Leukemia

J. Ritz, J. Griffin, 1982 .

Regulation of the production and function of granulocytes and monocytes.

S. Cannistra, J. Griffin, James D. Griffin, 1988, Seminars in hematology.

Expression of Myeloid Differentiation Antigens in Acute Myeloblastic Leukemia

J. Griffin, S. Schlossman, 1984 .

Identification of ILK as a novel therapeutic target for acute and chronic myeloid leukemia.

J. Melo, J. Griffin, R. Stone, 2015, Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis.

A naturally occurring bone marrow-chimeric primate. II. Environment dictates restriction on cytolytic T lymphocyte-target cell interactions

N. Letvin, J. Griffin, J. Picus, 1985, The Journal of experimental medicine.

Protein kinase activity associated with simian virus 40 T antigen.

D. Livingston, J. Griffin, G. Spangler, 1979, Proceedings of the National Academy of Sciences of the United States of America.

Induction of proliferation of purified human myeloid progenitor cells: a rapid assay for granulocyte colony-stimulating factors.

J. Griffin, S. Schlossman, R. Sullivan, 1984, Blood.

Acquisition of formyl peptide receptors during normal human myeloid differentiation

J. Griffin, R. Sullivan, H. Malech, 1987 .

Interferon‐γ induces expression of the interleukin 2 receptor gene in human monocytes

S. Cannistra, F. Herrmann, J. Griffin, 1987 .

Surface Antigens in a Patient With Blast Crisis of Chronic Myeloid Leukemia

E. Reinherz, J. Griffin, J. Daley, 2005 .

T-cell surface antigens in a patient with blast crisis of chronic myeloid leukemia

E. Reinherz, J. Griffin, J. Daley, 1983 .

Purification and characterization of fetal hematopoietic cells that express the common acute lymphoblastic leukemia antigen (CALLA)

J. Ritz, J. Griffin, L. Nadler, 1983, The Journal of experimental medicine.

Post‐transplant maintenance therapy in patients with FLT3‐mutated acute myeloid leukemia: Real‐world treatment patterns and outcomes

J. Griffin, M. Shah, Yan Song, 2021, European journal of haematology.

Ontogeny of human hematopoietic cells: analysis utilizing monoclonal antibodies.

R. Osathanondh, J. Griffin, L. Nadler, 1983, Journal of immunology.

Demonstration of interleukin-1 beta transcripts in acute myeloblastic leukemic cells by in situ hybridization.

J. Griffin, Y. Furukawa, Y. Kanakura, 1990, Leukemia.

Signaling Functions of the Tyrosine Residues in the βc Chain of the Granulocyte-Macrophage Colony-Stimulating Factor Receptor

J. Griffin, K. Okuda, R. Foster, 1997 .

Isolation and characterization of human B lymphocyte enriched populations. I. Purification of B cells by immune rosette depletion.

J. Griffin, L. Nadler, S. Schlossman, 1983, Journal of immunological methods.

Granulocyte colony-stimulating factor and its receptor.

G. Demetri, J. Griffin, 1991, Blood.

Regulation of surface expression of the granulocyte/macrophage colony-stimulating factor receptor in normal human myeloid cells.

S. Cannistra, J. Griffin, J. Miller, 1990, Proceedings of the National Academy of Sciences of the United States of America.

In vitro expression of colony-stimulating factor genes by human acute myeloblastic leukemia cells.

G. Demetri, S. Cannistra, J. Griffin, 1988, Experimental hematology.

Characterization of Two SHP-2-associated Binding Proteins and Potential Substrates in Hematopoietic Cells*

B. Neel, J. Griffin, Haihua Gu, 1997, The Journal of Biological Chemistry.

Signaling Domains of the βc Chain of the GM‐CSF/IL‐3/IL‐5 Receptor

J. Griffin, K. Okuda, R. Foster, 1999 .

Combination therapy with nilotinib for drug-sensitive and drug-resistant BCR-ABL-positive leukemia and other malignancies

J. Griffin, A. Nonami, E. Weisberg, 2014, Archives of Toxicology.

JAK2 gets histone H3 rolling.

J. Griffin, M. Sattler, 2009, Cancer cell.

Effects of anti-CD33 blocked ricin immunotoxin on the capacity of CD34+ human marrow cells to establish in vitro hematopoiesis in long-term marrow cultures.

M. Cutting, J. Griffin, V. L. La Russa, 1992, Experimental hematology.

Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species.

R. Salgia, J. Griffin, D. Chauhan, 2005, Blood.

Disposition of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving high-dose chemotherapy and autologous bone marrow support.

J. Griffin, Y. Kanakura, W. Petros, 1992, Blood.

A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader.

Dennis L. Buckley, J. Bradner, N. Gray, 2017, Cell chemical biology.

LAQ824 is a novel histone deacetylase inhibitor with significant activity against multiple myeloma: Results of a pre-clinical evaluation in vitro and in vivo.

N. Munshi, P. Richardson, N. Mitsiades, 2002 .

R. Salgia, J. Griffin, M. Sattler, 1996, The Journal of Biological Chemistry.

Functional consequences of monocyte IL-2 receptor expression. Induction of IL-1 beta secretion by IFN gamma and IL-2.

S. Cannistra, F. Herrmann, J. Griffin, 1989, Journal of immunology.

Idiopathic thrombocytopenia in association with extragonadal germ cell cancer.

J. Griffin, M. Garnick, 1983, Annals of internal medicine.

FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies

Sandra A. Moore, D. Fabbro, J. Kutok, 2005, Oncogene.

Signal transduction of steel factor and granulocyte-macrophage colony-stimulating factor: differential regulation of transcription factor and G1 cyclin gene expression, and of proliferation in the human factor-dependent cell line MO7.

F. Ajchenbaum‐Cymbalista, M. Hallek, J. Griffin, 1994, Leukemia.

Kinase Domain Mutations in JAK2V617F Confer Resistance to the Novel JAK2 Inhibitor Ruxolitinib

J. Griffin, M. Sattler, T. K. Chowdary, 2011 .

Clinical pharmacology of low-dose cytosine arabinoside

J. Griffin, D. Kufe, D. Spriggs, 1985 .

Conservation of myeloid surface antigens on primate granulocytes.

N. Letvin, J. Griffin, S. Schlossman, 1983, Blood.

Expression of the three myeloid cell-associated immunoglobulin G Fc receptors defined by murine monoclonal antibodies on normal bone marrow and acute leukemia cells.

C. Bloomfield, J. Griffin, J. Mcdermott, 1989, Blood.

Analysis of leukocyte differentiation antigens in blood and bone marrow from preleukemia (refractory anemia) patients using monoclonal antibodies.

J. Griffin, P. Hokland, J. Ellegaard, 1986, Blood.

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412

E. Estey, D. Neuberg, J. Griffin, 2004 .

Hematologic remission and cytogenetic improvement after treatment of stable‐phase chronic myelogenous leukemia with continuous infusion of low‐dose cytarabine

S. Cannistra, J. Griffin, M. Robertson, 1993, American journal of hematology.

cells STAT5 activation contributes to growth and viability in Bcr/Abl-transformed

J. Griffin, M. Sattler, D. Frank, 2013 .

Anti‐SARS‐CoV‐2 activity of targeted kinase inhibitors: Repurposing clinically available drugs for COVID‐19 therapy

N. Gray, R. Davey, M. Słabicki, 2022, Journal of medical virology.

Human bone marrow cytogenetics: growth factors stimulate metaphases for specific lineages.

A. de la Chapelle, J. Griffin, C. Bloomfield, 1989, Leukemia.

Differentiation of myeloid cells is accompanied by increased levels of pp60c-src protein and kinase activity.

T. Springer, T. Roberts, H. Piwnica-Worms, 1986, Proceedings of the National Academy of Sciences of the United States of America.

Surface marker anaylsis of acute myeloblastic leukemia: identifi- cation of differentiation-associated phenotypes.

Robert J. Mayer, James D. Griffin, D. Rosenthal, 1983 .

Induction of monocyte migration by recombinant macrophage colony-stimulating factor.

A. Mantovani, J. Griffin, J. Wang, 1988, Journal of immunology.

Discovery of a Highly Potent and Selective Indenoindolone Type 1 Pan-FLT3 Inhibitor.

N. Gray, J. Griffin, R. Stone, 2016, ACS medicinal chemistry letters.

An amino-indazole scaffold with spectrum selective kinase inhibition of FLT3, PDGFRα and kit.

P. Jänne, N. Gray, Wenjun Zhou, 2012, Bioorganic & medicinal chemistry letters.

Granulocyte‐Macrophage colony‐stimulating factor and steel factor induce phosphorylation of both unique and overlapping signal transduction intermediates in a human factor‐dependent hematopoietic cell line

M. Hallek, J. Griffin, E. Lepisto, 1992, Journal of cellular physiology.

Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.

Doriano Fabbro, Paul Manley, D. Fabbro, 2002, Cancer cell.

Expression of myeloid differentiation antigens on normal and malignant myeloid cells.

J. Ritz, J. Griffin, L. Nadler, 1981, The Journal of clinical investigation.

Human Bone Marrow Depleted of CD 33-Positive Cells Mediates Delayed but Durable Reconstitution of Hematopoiesis : Clinical Trial of MY 9 Monoclonal Antibody-Purged Autografts for the Treatment of Acute Myeloid Leukemia

A. Freedman, J. Griffin, R. Soiffer, 2003 .

J. Ritz, A. Freedman, J. Griffin, 1992, Blood.

Current Therapies Under Investigation for COVID-19.

N. Gray, J. Griffin, M. Sattler, 2020, Canadian journal of physiology and pharmacology.

Induction of differentiation of human myeloid leukemia cells by inhibitors of DNA synthesis.

J. Griffin, D. Kufe, P. Major, 1982, Experimental hematology.

Colony-stimulating factor gene expression in human acute myeloblastic leukemia cells is posttranscriptionally regulated.

J. Griffin, T. Ernst, A. Ritchie, 1989, Leukemia.

Clonogenic cells in acute myeloblastic leukemia.

J. Griffin, B. Löwenberg, J D Griffin, 1986, Blood.

Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration.

E. Kleinerman, N. Jaffe, R. Benjamin, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression.

M. Socinski, S. Cannistra, J. Griffin, 1988, The New England journal of medicine.

Monocytes enhance gamma-interferon-induced inhibition of myeloid progenitor cell growth through secretion of tumor necrosis factor.

S. Cannistra, J. Griffin, P. Groshek, 1988, Experimental hematology.

Surface Marker Analysis of Acute Myeloblastic Leukemia

J. Griffin, 1985 .

Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells.

H. Kitayama, J. Griffin, J. Ishikawa, 1991, Blood.

Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.

Doriano Fabbro, D. Fabbro, J. Griffin, 2005, Blood.

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Sandra A. Moore, S. Gabriel, T. Golub, 2005, Cancer cell.

After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies.

J. Griffin, D. DeAngelo, R. Stone, 2005, Blood.

Transforming activity of MECT1‐MAML2 fusion oncoprotein is mediated by constitutive CREB activation

J. Griffin, P. Gao, Yang Cao, 2005, The EMBO journal.

Repurposing of Kinase Inhibitors for Treatment of COVID-19

N. Gray, A. Parent, Jinhua Wang, 2020, Pharmaceutical Research.

Regulation of colony-stimulating factor production by normal and leukemic human cells

J. Griffin, T. Ernst, 1989, Immunologic research.

The CRTC1-MAML2 fusion is the major oncogenic driver in mucoepidermoid carcinoma

F. Kaye, W. Ni, J. Griffin, 2021, JCI insight.

t(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway

G. Tonon, F. Kaye, I. Kirsch, 2003, Nature Genetics.

A Genome-Wide Aberrant RNA Splicing in Patients with Acute Myeloid Leukemia Identifies Novel Potential Disease Markers and Therapeutic Targets

P. Pilarski, John Quackenbush, B. Haibe-Kains, 2013, Clinical Cancer Research.

Redirection to the bone marrow improves T cell persistence and antitumor functions

Clare L. Bennett, J. Griffin, T. Means, 2018, The Journal of clinical investigation.

Gene expression profiling analysis of CRTC1-MAML2 fusion oncogene-induced transcriptional program in human mucoepidermoid carcinoma cells

J. Griffin, Lizi Wu, Jian-Liang Li, 2015, BMC Cancer.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Donna Neuberg, Steven M Kornblau, Johannes Köster, 2016, Cancer cell.

The Notch coactivator, MAML1, functions as a novel coactivator for MEF2C-mediated transcription and is required for normal myogenesis.

R. Bronson, J. Griffin, P. Gao, 2006, Genes & development.

Immobilization of Notch ligand, Delta-1, is required for induction of notch signaling.

I. Bernstein, J. Griffin, L. Wu, 2000, Journal of cell science.

Using a zebrafish Danio rerio model system to study NOTCH1-induced T-cell leukaemia

J. Griffin, J. Chen, 2008 .

NOTCH1-induced T-cell leukemia in transgenic zebrafish

A. Look, J. Aster, J. Griffin, 2007, Leukemia.

Notch receptors and hematopoiesis.

J. Griffin, S. Kojika, James D. Griffin, 2001, Experimental hematology.

Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.

J. Griffin, B. Scheijen, M. Sattler, 2003, Advances in experimental medicine and biology.

Role of FLT3 in leukemia.

J. Griffin, D. Gilliland, 2002, Current opinion in hematology.

Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres.

S. Kesari, J. Griffin, P. Strack, 2010, Genes & cancer.

hematologic malignancies After chronic myelogenous leukemia: tyrosine kinase inhibitors in other

J. Griffin, D. DeAngelo, R. Stone, 2013 .

Activated FLT3 Receptor Tyrosine Kinase as a Therapeutic Target In Leukemia

J. Griffin, B. Scheijen, 2006 .

Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease

J. Griffin, B. Scheijen, 2002, Oncogene.

Molecular Cloning Of Human Paxillin, a Focal Adhesion Protein Phosphorylated by P210BCR/ABL(*)

S. Lo, R. Salgia, M. Hallek, 1995, The Journal of Biological Chemistry.

Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl

J. Griffin, D. Frank, N. Carlesso, 1996, The Journal of experimental medicine.

Molecular mechanisms of transformation by the BCR-ABL oncogene.

J. Griffin, M. Sattler, 2003, Seminars in hematology.

Critical role for Gab2 in transformation by BCR/ABL.

H. Iwasaki, B. Neel, J. Griffin, 2002, Cancer cell.

Involvement of the adapter protein CRKL in integrin-mediated adhesion

R. Salgia, J. Griffin, N. Uemura, 1999, Oncogene.

CRKL Links p210BCR/ABL with Paxillin in Chronic Myelogenous Leukemia Cells (*)

N. Heisterkamp, J. Groffen, R. Salgia, 1995, The Journal of Biological Chemistry.

Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines.

J. Griffin, E. Weisberg, 2000, Blood.

A chimeric receptor/oncogene that can be regulated by a ligand in vitro and in vivo.

A. D’Andrea, J. Griffin, R. A. Etten, 1997, The Journal of clinical investigation.

ARG tyrosine kinase activity is inhibited by STI571.

J. Griffin, D. Gilliland, K. Okuda, 2001, Blood.

Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification.

Rob Pieters, Todd R Golub, John H Kersey, 2003, Cancer cell.

Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro.

E. Sausville, J. Griffin, S. Kaufmann, 2002, Blood.

Granulocyte-macrophage colony-stimulating factor induces the expression of the CD11b surface adhesion molecule on human granulocytes in vivo.

M. Socinski, S. Cannistra, J. Griffin, 1988, Blood.

c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.

R. Salgia, J. Griffin, E. Fox, 2003, Cancer research.

FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML.

N. Gray, Qingsong Liu, J. Griffin, 2009, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia

P. D. Dal Cin, J. Aster, J. Bradner, 2009, Proceedings of the National Academy of Sciences.

Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression.

M. Meyerson, W. Sellers, P. Jänne, 2005, Cancer research.

Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs.

D. Neuberg, B. Neel, J. Griffin, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571

R. Salgia, J. Griffin, C. Stiles, 2000, Oncogene.

Inhibition of the deubiquitinating enzyme USP47 as a novel targeted therapy for hematologic malignancies expressing mutant EZH2

W. Ni, J. Griffin, Q. Liu, 2022, Leukemia.

Expression of colony-stimulating factor genes by normal human mesothelial cells and human malignant mesothelioma cells lines in vitro.

G. Demetri, J. Griffin, J. Rheinwald, 1989, Blood.

Expression of the macrophage colony-stimulating factor and c-fms genes in human acute myeloblastic leukemia cells.

E. Vellenga, J. Griffin, J. Horiguchi, 1988, The Journal of clinical investigation.

Targeting myeloid leukemia with a DT(390)-mIL-3 fusion immunotoxin: ex vivo and in vivo studies in mice.

J. Griffin, B. Blazar, D. Vallera, 1999, Protein engineering.

Expression of ras oncogenes in cultured human cells alters the transcriptional and posttranscriptional regulation of cytokine genes.

G. Demetri, J. Griffin, J. Rheinwald, 1990, The Journal of clinical investigation.

Selective Akt Inhibitors Synergize with Tyrosine Kinase Inhibitors and Effectively Override Stroma-Associated Cytoprotection of Mutant FLT3-Positive AML Cells

N. Gray, Qingsong Liu, C. Mitsiades, 2013, PloS one.

Immunological and cytogenetic studies in two cases of B-cell acute lymphoblastic leukemia (Burkitt's type).

J. Griffin, R. Mayer, C. Henkle, 1983, Cancer genetics and cytogenetics.

Heterogeneous expression of the product of the retinoblastoma susceptibility gene in primary human leukemia cells.

M. Belvin, J. Decaprio, J. Griffin, 1991, Oncogene.

Biology of acute myeloid leukaemia.

J. Griffin, H. Messner, 1986, Clinics in haematology.

Stable expression of small interfering RNA sensitizes TEL-PDGFbetaR to inhibition with imatinib or rapamycin.

D. Fabbro, K. Kocher, D. Neuberg, 2004, The Journal of clinical investigation.

Differentiation patterns in the blastic phase of chronic myeloid leukemia.

D. Rosenthal, J. Ritz, J. Griffin, 1983, Blood.

Gene therapy for chronic myelogenous leukemia (CML): a retroviral vector that renders hematopoietic progenitors methotrexate-resistant and CML progenitors functionally normal and nontumorigenic in vivo

C. Verfaillie, J. Griffin, R. Zhao, 1997 .

p130CAS Forms a Signaling Complex with the Adapter Protein CRKL in Hematopoietic Cells Transformed by the BCR/ABL Oncogene*

James D. Griffin, Naoki Uemura, Ravi Salgia, 1996, The Journal of Biological Chemistry.

Alternative splicing in chronic myeloid leukemia (CML): a novel therapeutic target?

P. Pilarski, J. Griffin, R. Stone, 2013, Current cancer drug targets.

Clinical importance of myeloid antigen expression in adult acute lymphoblastic leukemia.

I Royston, C. Bloomfield, J. Griffin, 1987, The New England journal of medicine.

High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia.

S. Fröhling, R. Levine, R. Berger, 2007, Blood.

Discovery of a Potent and Selective DDR1 Receptor Tyrosine Kinase Inhibitor

Sam W. Lee, N. Gray, Qingsong Liu, 2013, ACS chemical biology.

Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097

M. Wiesmann, J. Griffin, Irene Simkin, 2015, Molecular Cancer Therapeutics.

PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR.

Annie P. Moseman, D. Kwiatkowski, J. Griffin, 2007, The Journal of clinical investigation.

Aberrantly activated AREG–EGFR signaling is required for the growth and survival of CRTC1–MAML2 fusion-positive mucoepidermoid carcinoma cells

J. Griffin, J. Li, H. Shen, 2014, Oncogene.

A pericentric inversion of chromosome 16 is associated with dysplastic marrow eosinophils in acute myelomonocytic leukemia.

J. Griffin, C. Henkle, H. Weinstein, 1984, Blood.

MAML 1 , a human homologue of Drosophila Mastermind , is a transcriptional coactivator for NOTCH receptors

J. Aster, S. Blacklow, S. Artavanis-Tsakonas, 2000 .

A Robust Error Model for iTRAQ Quantification Reveals Divergent Signaling between Oncogenic FLT3 Mutants in Acute Myeloid Leukemia*

Yi Zhang, Manor Askenazi, Jarrod A Marto, 2009, Molecular & Cellular Proteomics.

The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRβ and FIP1L1-PDGFRα in vitro and in vivo

Sandra A. Moore, D. Fabbro, J. Griffin, 2005 .

The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo.

Sandra A. Moore, D. Fabbro, J. Griffin, 2005, Blood.

Epidermal Growth Factor – Independent Transformation of Ba / F 3 Cells with Cancer-Derived Epidermal Growth Factor Receptor Mutants Induces Gefitinib-Sensitive Cell Cycle Progression

M. Meyerson, W. Sellers, P. Jänne, 2005 .

Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells.

J. Griffin, I. Galinsky, A. Kung, 2008, Blood.

The Notch Regulator MAML1 Interacts with p53 and Functions as a Coactivator*

Goberdhan P Dimri, A. Stanculescu, J. Griffin, 2007, Journal of Biological Chemistry.

Tyrosine phosphorylation of Shc is not required for proliferation or viability signaling by granulocyte-macrophage colony-stimulating factor in hematopoietic cell lines.

J. Griffin, R. Inhorn, M. Durstin, 1996, Journal of immunology.

C. Verfaillie, J. Griffin, R. Zhao, 1997, Blood.

PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease.

D. Fabbro, D. Neuberg, J. Kutok, 2003, Cancer cell.

on chronic myelogenous leukemia cells in vitro Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410)

E. Sausville, J. Griffin, P. Svingen, 2013 .

Bone marrows of non-Hodgkin's lymphoma patients with a bcl-2 translocation can be purged of polymerase chain reaction-detectable lymphoma cells using monoclonal antibodies and immunomagnetic bead depletion.

J. Gribben, A. Freedman, J. Griffin, 1992, Blood.

A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells.

J. Griffin, D. Linch, K. Sabbath, 1984, Leukemia research.

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

Donna Neuberg, Doriano Fabbro, Arghya Ray, 2005, Cancer cell.

Heterogeneity of clonogenic cells in acute myeloblastic leukemia.

J. Griffin, K. Sabbath, E. Ball, 1985, The Journal of clinical investigation.

Inhibitors of the Transcription Factor STAT3 Decrease Growth and Induce Immune Response Genes in Models of Malignant Pleural Mesothelioma (MPM)

C. Paweletz, R. Bueno, R. Salgia, 2020, Cancers.

Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells

Arghya Ray, Jan Cools, Leigh Zawel, 2007, Molecular Cancer Therapeutics.

Bcr/Abl activates transcription of the Bcl-X gene through STAT5.

J. Griffin, F. Gesbert, James D. Griffin, 2000, Blood.

Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity.

D. Fabbro, J. Griffin, A. Kung, 2006, Gastroenterology.

Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study Identification of BCR-ABL point mutations conferring resistance to the

J. Mestan, J. Griffin, S. Cowan-Jacob, 2013 .

Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study.

J. Mestan, J. Griffin, S. Cowan-Jacob, 2005, Blood.

Steel Factor Induces Tyrosine Phosphorylation of CRKL and Binding of CRKL to a Complex Containing c-Kit, Phosphatidylinositol 3-Kinase, and p120CBL*

R. Salgia, J. Griffin, S. Verma, 1997, The Journal of Biological Chemistry.

Involvement of p130Cas and p105HEF1, a Novel Cas-like Docking Protein, in a Cytoskeleton-dependent Signaling Pathway Initiated by Ligation of Integrin or Antigen Receptor on Human B Cells*

R. Salgia, B. Druker, A. Freedman, 1997, The Journal of Biological Chemistry.

Prediction of Resistance to Small Molecule FLT3 Inhibitors

Doriano Fabbro, Peter Marynen, Pascal Furet, 2004, Cancer Research.

Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms

J. Griffin, M. Sattler, T. K. Chowdary, 2011, Leukemia.

BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair.

J. Griffin, D. Weinstock, K. Podar, 2009, Blood.

Targeted Therapy with Imatinib: An Exception or a Rule?

J. Mestan, D. Fabbro, P. Furet, 2005 .

Resistance to imatinib (Glivec): update on clinical mechanisms.

J. Griffin, E. Weisberg, 2003, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors

N. Gray, Wenjun Zhou, H. Choi, 2010, Molecular Cancer Therapeutics.

Molecular Cancer apeutics apeutic Discovery overy and Characterization of Novel Mutant Ther 3 Kinase Inhibitors

Ellen, N. Gray, Wenjun Zhou, 2010 .

Development of 'DFG-out' inhibitors of gatekeeper mutant kinases.

N. Gray, H. Choi, J. Griffin, 2012, Bioorganic & medicinal chemistry letters.

Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants.

James D. Griffin, Andrew L. Kung, Taebo Sim, 2010, Blood.

Acute myeloid leukemia and acute promyelocytic leukemia.

Bob Löwenberg, J. Griffin, M. Tallman, 2003, Hematology. American Society of Hematology. Education Program.

Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies

N. Gray, C. Mitsiades, J. Griffin, 2014, Leukemia.

Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML.

M. Meyerson, W. Sellers, Jeffrey C. Lee, 2004, Blood.

Spotlight on midostaurin in the treatment of FLT3-mutated acute myeloid leukemia and systemic mastocytosis: design, development, and potential place in therapy

J. Griffin, P. Manley, M. Sattler, 2017, OncoTargets and therapy.

Wnt/β-catenin Pathway Modulates the Sensitivity of the Mutant FLT3 Receptor Kinase Inhibitors in a GSK-3β Dependent Manner.

J. Griffin, Jingrui Jiang, 2010, Genes & cancer.

Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells.

Pascal Furet, Guido Bold, Arghya Ray, 2008, Blood.

Autocrine secretion of GM-CSF in acute myeloblastic leukemia.

J. Griffin, D. Young, 1986, Blood.

Identification and characterization of a novel activating mutation of the FLT3 tyrosine kinase in AML

M. Meyerson, W. Sellers, R. Bo, 2004 .

Following the cytokine signaling pathway to leukemogenesis: a chronology.

Kendall A. Smith, J. Griffin, James D Griffin, 2008, The Journal of clinical investigation.

BCR/ABL Regulates Expression of the Cyclin-dependent Kinase Inhibitor p27Kip1 through the Phosphatidylinositol 3-Kinase/AKT Pathway*

M. Loda, W. Sellers, S. Signoretti, 2000, The Journal of Biological Chemistry.

Selective Cytotoxicity of the SM 1 Monoclonal Antibody towards Small Cell Carcinoma of the Lung 1

R. Stahel, J. Griffin, M. Mabry, 2006 .

Use of surface marker analysis to predict outcome of adult acute myeloblastic leukemia.

C. Bloomfield, C. Schiffer, J. Griffin, 1986, Blood.

The application of monoclonal antibodies for the detection and classification of AML

J. Griffin, 1986 .

Selective cytotoxicity of the SM1 monoclonal antibody towards small cell carcinoma of the lung.

R. Stahel, J. Griffin, M. Mabry, 1985, Cancer research.

Surface marker analysis of acute myeloblastic leukemia: identification of differentiation-associated phenotypes.

Weinstein, D. Rosenthal, J. Griffin, 1983, Blood.

Generation time of leukaemic blast progenitor cells.

M. Minden, J. Griffin, D. Kufe, 1983, Cell and tissue kinetics.

Establishment of an interleukin 2-dependent T cell line derived from a patient with severe aplastic anemia, which inhibits in vitro hematopoiesis.

F. Herrmann, J. Griffin, K. Meyer zum Büschenfelde, 1986, Journal of immunology.

T cell regulation of myelopoiesis: analysis at a clonal level.

E. Reinherz, J. Griffin, S. Meuer, 1984, Journal of immunology.

Proliferation of human myeloid leukemia cell line associated with the tyrosine-phosphorylation and activation of the proto-oncogene c-kit product

H. Kitayama, J. Griffin, T. Nishiura, 1991 .

Proliferation of human myeloid leukemia cell line associated with the tyrosine-phosphorylation and activation of the proto-oncogene c-kit product.

H. Kitayama, B. Druker, J. Griffin, 1991, Blood.

Clinical applications of colony-stimulating factors.

J. Griffin, 1988, Oncology.

Effects of recombinant human granulocyte‐macrophage colony‐stimulating factor (GM‐CSFrh) on transmembrane electrical potentials in granulocytes: Relationship between enhancement of ligand‐mediated depolarization and augmentation of superoxide anion (O −2 ) production

J. Griffin, E. Simons, A. Gadenne, 1989, Journal of cellular physiology.

Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells

D. McMillin, C. Mitsiades, J. Griffin, 2008, Molecular Cancer Therapeutics.

Myeloid and erythroid progenitor cells from normal bone marrow adhere to collagen type I.

S. Cannistra, J. Griffin, M. Koenigsmann, 1992, Blood.

Hemopoietins in oncology: factoring out myelosuppression.

J. Griffin, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Enrichment of myeloid progenitor cells from normal human bone marrow using an immune-rosette technique.

G. Curt, J. Griffin, R. Fine, 1985, Experimental hematology.

The action of bryostatin on normal human hematopoietic progenitors is mediated by accessory cell release of growth factors.

G. Demetri, J. Griffin, C. Civin, 1990, Blood.

Granulocyte-macrophage colony-stimulating factor, interleukin-3, and steel factor induce rapid tyrosine phosphorylation of p42 and p44 MAP kinase.

M. Hallek, B. Druker, J. Griffin, 1992, Blood.

Phase II Evaluation of N-Trifluoroacetyladriamycin-14-Valerate (AD 32)

M. Sack, J. Griffin, M. Israel, 1982 .

NOTCH1-Induced T-Cell Leukemia in Transgenic Zebrafish.

A. Look, J. Aster, J. Griffin, 2006 .

Discovery of a highly potent FLT3 kinase inhibitor for FLT3-ITD-positive AML

X. Liu, K. Yu, J. Griffin, 2016, Leukemia.

The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations

N. Gray, Jinhua Wang, J. Griffin, 2020, Journal of cellular and molecular medicine.

Novel Transforming Mutations of CBL in Human Acute Myeloid Leukemia

R. Salgia, J. Griffin, H. Band, 2008 .

Transforming growth factor-beta inhibits phosphorylation of the retinoblastoma susceptibility gene product in human monocytic leukemia cell line JOSK-I.

J. Griffin, Y. Furukawa, M. Saito, 1992, The Journal of biological chemistry.

Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM)

R. Bueno, Prakash Kulkarni, R. Salgia, 2021, British Journal of Cancer.

Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism

Sarah A. Boswell, W. Hahn, P. Sorger, 2020, Scientific Reports.

Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming

D. Neuberg, R. Salgia, J. Griffin, 2017, Oncotarget.

Novel Oncogenic Mutations of CBL in Human Acute Myeloid Leukemia That Activate Growth and Survival Pathways Depend on Increased Metabolism*

R. Larson, M. Carroll, R. Salgia, 2010, The Journal of Biological Chemistry.

Discovery of a selective irreversible BMX inhibitor for prostate cancer.

A. Look, N. Gray, Qingsong Liu, 2013, ACS chemical biology.

Studies of TAK 1-centered polypharmacology with novel covalent TAK 1 inhibitors

D. Lauffenburger, P. Sorger, N. Gray, 2017 .

Structure-guided development of covalent TAK1 inhibitors.

P. Sorger, N. Gray, K. Westover, 2017, Bioorganic & medicinal chemistry.

Upregulation of IGF1R by Mutant RAS in Leukemia and Potentiation of RAS Signaling Inhibitors by Small-Molecule Inhibition of IGF1R

Kwok-Kin Wong, N. Gray, Qingsong Liu, 2014, Clinical Cancer Research.

Evaluation of ERK as a therapeutic target in acute myelogenous leukemia

N. Gray, Jinhua Wang, J. Griffin, 2019, Leukemia.

Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach.

N. Gray, Qingsong Liu, J. Griffin, 2015, Blood.

Autologous peripheral stem cell transplantation of the blastic phase of chronic myeloid leukemia following sequential high‐dose cytosine arabinoside and melphalan

J. Griffin, U. Matulonis, G. Canellos, 1994, American journal of hematology.

at a clonal level In vitro regulation of human hematopoiesis by natural killer cells: analysis

J. Ritz, F. Herrmann, J. Griffin, 2011 .

CD2 is involved in maintenance and reversal of human alloantigen- specific clonal anergy

J. Gribben, G. Freeman, J. Griffin, 1994, The Journal of experimental medicine.

Acute undifferentiated leukemia: induction of partial differentiation by phorbol ester.

J. Griffin, T. Shkolnik, S. Schlossman, 1985, Leukemia research.

Interferon-gamma induces expression of the interleukin 2 receptor gene in human monocytes.

S. Cannistra, F. Herrmann, J. Griffin, 1987, European journal of immunology.

Pharmacological profile of the FLT3-Tyrosine Kinase Inhibitor AST487

D. Fabbro, J. Brueggen, G. Bold, 2005 .

monocytes Independent regulation of M-CSF and G-CSF gene expression in human

E. Vellenga, J. Griffin, T. Ernst, 2011 .

Morphologic characteristics of erythroleukemia (Acute Myeloid Leukemia; FAB‐M6): A CALGB study

C. Bloomfield, J. Griffin, R. Mayer, 1995, American journal of hematology.

Identification of functionally distinct domains of human granulocyte- macrophage colony-stimulating factor using monoclonal antibodies

S. Cannistra, J. Griffin, K. Kaushansky, 1991 .

Identification of functionally distinct domains of human granulocyte-macrophage colony-stimulating factor using monoclonal antibodies.

S. Cannistra, J. Griffin, K. Kaushansky, 1991, Blood.

Differentiation-Associated Stages of Clonogenic Cells in Acute Myeloblastic Leukemia Identified by Monoclonal Antibodies

J. Griffin, K. Sabbath, 1986 .

Expression of an antigen defined by a monoclonal antibody (SA-1) on normal and malignant cells.

J. Griffin, N. Nissen, T. Plesner, 2009, Scandinavian journal of haematology.

Microgranular Acute Promyelocytic Leukemia Diagnosed by Flow Cytometry

J. Griffin, J. Hudson, A. Flint, 1983 .

The use of monoclonal antibodies in the characterization of myeloid leukemias.

J. Griffin, 1987, Hematologic pathology.

The Role of Protein Composition in Specifying Nuclear Inclusion Formation in Polyglutamine Disease*

H. Paulson, J. Griffin, Y. Chai, 2001, The Journal of Biological Chemistry.

Chronic granulocytic leukemia: the heterogeneity of stem cell differentiation within a single disease entity.

J. Griffin, G. Canellos, 1985, Seminars in oncology.

T-cell surface antigens in a patient with blast crisis of chronic myeloid leukemia.

E. Reinherz, J. Griffin, J. Daley, 1983, Blood.

NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML.

P. Pilarski, John Quackenbush, Benjamin Haibe-Kains, 2014, Blood.

Low dose ara-C administered by continuous subcutaneous infusion: a pharmacologic evaluation.

J. Griffin, D. Kufe, D. Spriggs, 1986, Cancer drug delivery.

Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML

K. Yu, J. Griffin, R. Stone, 2016, Leukemia.

Inhibition of SDF-1-induced migration of oncogene-driven myeloid leukemia by the L-RNA aptamer (Spiegelmer), NOX-A12, and potentiation of tyrosine kinase inhibition

J. Griffin, R. Stone, P. Manley, 2017, Oncotarget.

Characterization of myeloid leukemias with monoclonal antibodies 3C5 and MY9

D. Catovsky, J. Griffin, E. Matutes, 1985, Hematological oncology.

Interaction of the receptor tyrosine kinase p145c‐kit with the p210bcr/abl kinase in myeloid cells

A. Ullrich, M. Warmuth, M. Hallek, 1996, British journal of haematology.

Simultaneous inhibition of Vps34 kinase would enhance PI3Kδ inhibitor cytotoxicity in the B-cell malignancies

Qingsong Liu, J. Griffin, S. Fernandes, 2016, Oncotarget.

Characterization of selective and potent PI3Kδ inhibitor (PI3KD-IN-015) for B-Cell malignances

Qingsong Liu, J. Griffin, S. Fernandes, 2016, OncoTarget.

BCR/ABL Induces Expression of Vascular Endothelial Growth Factor and its Transcriptional Activator, Hypoxia Inducible Factor-1α, through a Pathway Involving PI3-Kinase and the Mammalian Target of Rapamycin (mTOR)

J. Griffin, P. Valent, C. Sillaber, 2002 .

Structure of a pseudokinase domain switch that controls oncogenic activation of Jak kinases

Chae Un Kim, S. Ficarro, J. Marto, 2013, Nature Structural &Molecular Biology.

Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth‐inhibitory and VEGF‐suppressive effects of rapamycin in leukemic cells

C. Marosi, O. Wagner, B. Druker, 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Hypoxia potentiates Notch signaling in breast cancer leading to decreased E-cadherin expression and increased cell migration and invasion

J. Griffin, Jing Chen, J. Chen, 2009, British Journal of Cancer.

Regulation of leukocyte migration by activation of the leukocyte adhesion molecule-1 (LAM-1) selectin

J. Griffin, J. M. Munro, T. Tedder, 1991, Nature.

Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia

X. Liu, M. Eck, J. Griffin, 2016, Leukemia.

Treatment patterns of chronic myelogenous leukemia patients with suboptimal responses to imatinib.

J. Griffin, E. Wu, J. Signorovitch, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inhibition of p21ras activation blocks proliferation but not differentiation of interleukin-3-dependent myeloid cells.

J. Griffin, K. Okuda, T. Ernst, 1994, The Journal of biological chemistry.

Treatment of the Elastic Phase of Chronic Myelogenous Leukemia with High‐Dose Cytosine Arabinoside

D. Rosenthal, J. Griffin, T. Ernst, 1988, American Journal of Clinical Oncology.

Use of a temperature-sensitive mutant to define the biological effects of the p210BCR-ABL tyrosine kinase on proliferation of a factor-dependent murine myeloid cell line.

B. Druker, J. Griffin, N. Carlesso, 1994, Oncogene.

The JAK2V617F oncogene requires expression of inducible phosphofructokinase/fructose-bisphosphatase 3 for cell growth and increased metabolic activity

O. Abdel-Wahab, R. Levine, J. Griffin, 2011, Leukemia.

Tyrosine phosphorylation of the product of the c-cbl protooncogene is [corrected] induced after integrin stimulation.

R. Salgia, B. Druker, A. Freedman, 1997, Experimental hematology.

Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL–transformed hematopoietic cell lines

J. Griffin, E. Weisberg, 2000 .

Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia

J. Griffin, V. Bollu, E. Wu, 2010, Current medical research and opinion.

The phosphatidylinositol polyphosphate 5-phosphatase SHIP and the protein tyrosine phosphatase SHP-2 form a complex in hematopoietic cells which can be regulated by BCR/ABL and growth factors

Ravi Salgia, R. Salgia, J. Griffin, 1997, Oncogene.

3D tissue engineered plasma cultures support leukemic proliferation and induces drug resistance

J. Dipersio, J. Griffin, A. Azab, 2021, Leukemia & lymphoma.

respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412 Patients with acute myeloid leukemia and an activating mutation in FLT3

E. Estey, D. Neuberg, J. Griffin, 2013 .

FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse model

D. Fabbro, J. Griffin, D. Gilliland, 2005, Oncogene.

Gene expression profiling analysis of CRTC1-MAML2 fusion oncogene-induced transcriptional program in human mucoepidermoid carcinoma cells

J. Griffin, Jie Chen, Lizi Wu, 2015, BMC Cancer.

Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2

J. Griffin, Q. Liu, E. Weisberg, 2023, MedComm.

PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial.

Jennifer Hayes Clark, E. Estey, D. Neuberg, 2004, Annals of hematology.

A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting

J. Griffin, E. Wu, Lei Chen, 2012, Current medical research and opinion.

Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML

J. Griffin, E. Weisberg, Zheng Zhao, 2016, Oncotarget.

Interferon-gamma increases the expression of the gene encoding the beta subunit of the granulocyte-macrophage colony-stimulating factor receptor.

M. Hallek, J. Griffin, E. Lepisto, 1992, Blood.

Southern blot analysis of BII cell line--a putative variant of HL-60.

K. Huebner, J. Griffin, D. Kufe, 1987, Leukemia.

Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming

D. Neuberg, R. Salgia, J. Griffin, 2017, Oncotarget.

SB1518: A Potent and Orally Active JAK2 Inhibitor for the Treatment of Myeloproliferative Disorders.

Z. Bonday, J. Wood, J. Griffin, 2007 .

Inhibition of the deubiquitinase USP10 induces degradation of SYK

N. Gray, Jinhua Wang, J. Griffin, 2020, British Journal of Cancer.

Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase

K. Stegmaier, S. Lazo, J. Griffin, 2017, Oncotarget.

Effects of interferon-gamma on proto-oncogene expression during induction of human monocytic differentiation.

J. Griffin, D. Kufe, E. Sariban, 1987, Journal of immunology.

Signaling domains of the beta c chain of the GM-CSF/IL-3/IL-5 receptor.

J. Griffin, K. Okuda, R. Foster, 1999, Annals of the New York Academy of Sciences.

The role of colony stimulating factors in leukaemogenesis.

J. Griffin, D. Young, Young Dc, 1986, Clinics in haematology.

Notch1 activation enhances proliferation via activation of cdc2 and delays differentiation of myeloid progenitors.

J. Griffin, K. Goi, T. Inukai, 2018, Leukemia research.

Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase.

K. Stegmaier, S. Lazo, J. Griffin, 2017, Oncotarget.

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

J. Mestan, J. Griffin, S. Cowan-Jacob, 2006, British Journal of Cancer.

STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells.

J. Griffin, M. Sattler, D. Frank, 2000, Blood.

Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism

Sarah A. Boswell, W. Hahn, P. Sorger, 2020, Scientific Reports.

PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial.

Jennifer Hayes Clark, E. Estey, D. Neuberg, 2004, Annals of hematology.

The application of monoclonal antibodies for the detection and classification of AML

J. Griffin, 1986 .

FLT3 tyrosine kinase as a target in acute leukemias.

J. Griffin, 2004, The hematology journal : the official journal of the European Haematology Association.

Pathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cells

D. Neuberg, G. Tonon, J. Asara, 2015, Leukemia.

Inhibitors of Protein Kinases and Protein Phosphates Contributors

L. Meijer, D. Fabbro, M. Yacoub, 2005 .

The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment

P. Richardson, J. Wood, Sigui Li, 2002, Cancer research.

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412

E. Estey, D. Neuberg, J. Griffin, 2004 .

Interaction maps for kinase inhibitors

J. Griffin, James D Griffin, 2005, Nature Biotechnology.

Transforming growth factor-beta inhibits phosphorylation of the retinoblastoma susceptibility gene product in human monocytic leukemia cell line JOSK-I.

J. Griffin, Y. Furukawa, M. Saito, 1992, The Journal of biological chemistry.

Enzymatic activities associated with the SV40 large T antigen.

D. Livingston, J. Griffin, G. Spangler, 1980, Cold Spring Harbor symposia on quantitative biology.

Effects of 1-beta-D-arabinofuranosylcytosine and phorbol ester on differentiation of human K562 erythroleukemia cells.

T. Watanabe, J. Griffin, D. Kufe, 1985, Molecular Pharmacology.

Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification.

T. Golub, S. Armstrong, S. Korsmeyer, 2003, Cancer cell.

Enforced CDK4 expression in a hematopoietic cell line confers resistance to the G1 arrest induced by ionizing radiation

M. Ewen, J. Griffin, V. F. Liu, 1998, Oncogene.

Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells.

J. Griffin, J. Ishikawa, Y. Kanakura, 1991, Blood.

PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR.

Annie P. Moseman, D. Kwiatkowski, J. Griffin, 2007, The Journal of clinical investigation.

Leukemia stem cells and constitutive activation of NF-kappaB.

J. Griffin, 2001, Blood.

Acquisition of formyl peptide receptors during normal human myeloid differentiation.

J. Griffin, H. Malech, R. Sullivan, 1987, Blood.

Spotlight on midostaurin in the treatment of FLT3-mutated acute myeloid leukemia and systemic mastocytosis: design, development, and potential place in therapy

J. Griffin, P. Manley, M. Sattler, 2017, OncoTargets and therapy.

Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia

J. Griffin, V. Bollu, E. Wu, 2010, Current medical research and opinion.

Morphologic and cytochemical characteristics of acute promyelocytic leukemia

C. Bloomfield, C. Schiffer, J. Griffin, 1989, American journal of hematology.

Signaling functions of the tyrosine residues in the betac chain of the granulocyte-macrophage colony-stimulating factor receptor.

J. Griffin, K. Okuda, L. Smith, 1997, Blood.

After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies.

J. Griffin, D. DeAngelo, R. Stone, 2005, Blood.

Simultaneous Administration of AMN107 and Imatinib in the Treatment of Imatinib-Sensitive and Imatinib-Resistant Chronic Myeloid Leukemia.

J. Griffin, E. Weisberg, 2005 .

Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach.

N. Gray, Qingsong Liu, J. Griffin, 2015, Blood.

Upregulation of IGF1R by Mutant RAS in Leukemia and Potentiation of RAS Signaling Inhibitors by Small-Molecule Inhibition of IGF1R

N. Gray, Qingsong Liu, C. Mitsiades, 2014, Clinical Cancer Research.

Hypomethylating agent decitabine sensitizes diffuse large B-cell lymphoma to venetoclax

J. Griffin, M. Davids, L. Rui, 2023, Haematologica.

O-306 Novel somatic mutations in the juxtamembrane domain of c-Met in small cell lung cancer: implications in cytoskeletal functions and cell motility

R. Salgia, J. Griffin, E. Fox, 2003 .

The Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor PTK 787 / ZK 222584 Inhibits Growth and Migration of Multiple Myeloma Cells in the Bone Marrow Microenvironment 1

N. Munshi, P. Richardson, J. Wood, 1998 .